Senior Director, HEOR/RWE - Lung

Job description

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Senior Director, HEOR/RWE is responsible for providing input on the strategy and executing HEOR plans and activities related to all Revolution Medicines assets intended for use in non-small cell lung cancer (NSCLC). They will be accountable for demonstrating the value of Revolution Medicines products to healthcare organizations, allowing them to make informed decisions. They will work closely with the Medical Affair...